WallStreetZenWallStreetZen

NASDAQ: AMED
Amedisys Inc Stock Forecast, Predictions & Price Target

Open Broker Account
OverviewForecast
EarningsDividendOwnership

Analyst price target for AMED

Based on 16 analysts offering 12 month price targets for Amedisys Inc.
Min Forecast
$95.00-10.47%
Avg Forecast
$159.50+50.32%
Max Forecast
$221.00+108.27%

Should I buy or sell AMED stock?

Based on 16 analysts offering ratings for Amedisys Inc.
Buy
Strong Buy
5 analysts 31.25%
Buy
6 analysts 37.5%
Hold
3 analysts 18.75%
Sell
1 analysts 6.25%
Strong Sell
1 analysts 6.25%

Be the first to know when Wall Street analysts revise their AMED stock forecasts and price targets.

AMED stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
UBS
Top 24%
77
Strong SellDowngrades$95.00-10.47%2022-08-02
Raymond James
Bottom 21%
21
BuyMaintains$140.00+31.94%2022-08-01
Barclays
Bottom 11%
11
Strong BuyMaintains$154.00+45.13%2022-07-29
Benchmark
Top 5%
96
Strong BuyMaintains$165.00+55.50%2022-07-28
Truist Securities
Top 9%
92
Strong BuyMaintains$150.00+41.36%2022-07-14
Stifel Nicolaus
Bottom 32%
32
HoldInitiates Coverage On$128.00+20.63%2022-06-29
Bank of America
Top 27%
74
SellDowngrades$102.00-3.87%2022-06-21
Deutsche Bank
Bottom 29%
29
Strong BuyMaintains$175.00+64.92%2022-06-21
Stephens & Co.
Top 8%
93
HoldMaintains$125.00+17.80%2022-06-21
SVB Leerink
Bottom 32%
32
HoldMaintains$107.00+0.84%2022-06-21

1 of 2

Forecast return on equity

Is AMED forecast to generate an efficient return?
Company
19.78%
Industry
-76.17%
Market
118.57%
AMED's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is AMED forecast to generate an efficient return on assets?
Company
9.74%
Industry
8.81%
AMED is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

AMED earnings per share forecast

What is AMED's earnings per share in the next 3 years based on estimates from 11 analysts?
Avg 1 year Forecast
$5.34+23.9%
Avg 2 year Forecast
$5.95+38.05%
Avg 3 year Forecast
$6.91+60.32%
AMED's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

AMED revenue forecast

What is AMED's revenue in the next 3 years based on estimates from 10 analysts?
Avg 1 year Forecast
$2.3B+3.8%
Avg 2 year Forecast
$2.5B+13.46%
Avg 3 year Forecast
$2.8B+24.58%
AMED's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

AMED earnings growth forecast

How is AMED forecast to perform vs Medical Care Facilities companies and vs the US market?
Company
16.43%
Industry
4.51%
Market
16.42%
AMED's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
AMED's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
AMED's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

AMED revenue growth forecast

How is AMED forecast to perform vs Medical Care Facilities companies and vs the US market?
Company
7.48%
Industry
8.78%
Market
8.46%
AMED's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
AMED's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

AMED vs Medical Care Facility Stocks

TickerPricePrice TargetUp/downsideConsensus
AMED$106.11$159.50+50.32%Buy
SEM$23.02$35.00+52.04%Buy
LFST$7.45$10.00+34.23%Hold
CANO$8.87$10.44+17.75%Buy
ENSG$79.64$95.25+19.60%Buy
View Top Medical Care Facility Stocks

Amedisys Stock Forecast FAQ

Is Amedisys Stock a good buy in 2022, according to Wall Street analysts?

The consensus among 16 Wall Street analysts covering (NASDAQ: AMED) stock is to Buy AMED stock.

Out of 16 analysts, 5 (31.25%) are recommending AMED as a Strong Buy, 6 (37.5%) are recommending AMED as a Buy, 3 (18.75%) are recommending AMED as a Hold, 1 (6.25%) are recommending AMED as a Sell, and 1 (6.25%) are recommending AMED as a Strong Sell.

If you're new to stock investing, here's how to buy Amedisys stock.

What is AMED's earnings growth forecast for 2022-2024?

(NASDAQ: AMED) Amedisys's forecast annual earnings growth rate of 16.43% is forecast to beat the US Medical Care Facilities industry's average forecast earnings growth rate of 4.51%, and and it is also forecast to beat the US market's average forecast earnings growth rate of 16.42%.

Amedisys's earnings in 2022 is $140,303,000.On average, 11 Wall Street analysts forecast AMED's earnings for 2022 to be $173,247,441, with the lowest AMED earnings forecast at $168,380,940, and the highest AMED earnings forecast at $176,491,775. On average, 11 Wall Street analysts forecast AMED's earnings for 2023 to be $193,037,879, with the lowest AMED earnings forecast at $180,060,543, and the highest AMED earnings forecast at $208,610,683.

In 2024, AMED is forecast to generate $224,183,486 in earnings, with the lowest earnings forecast at $187,522,511 and the highest earnings forecast at $247,542,692.

What is AMED's revenue growth forecast for 2022-2024?

(NASDAQ: AMED) Amedisys's forecast annual revenue growth rate of 7.48% is not forecast to beat the US Medical Care Facilities industry's average forecast revenue growth rate of 8.78%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 8.46%.

Amedisys's revenue in 2022 is $2,215,949,000.On average, 10 Wall Street analysts forecast AMED's revenue for 2022 to be $74,621,371,354, with the lowest AMED revenue forecast at $74,139,522,853, and the highest AMED revenue forecast at $74,944,442,143. On average, 10 Wall Street analysts forecast AMED's revenue for 2023 to be $81,570,053,686, with the lowest AMED revenue forecast at $78,152,764,135, and the highest AMED revenue forecast at $84,977,545,348.

In 2024, AMED is forecast to generate $89,567,045,252 in revenue, with the lowest revenue forecast at $86,218,178,708 and the highest revenue forecast at $91,376,345,493.

What is AMED's forecast return on assets (ROA) for 2022-2025?

(NASDAQ: AMED) forecast ROA is 9.74%, which is higher than the forecast US Medical Care Facilities industry average of 8.81%.

What is AMED's Price Target?

According to 16 Wall Street analysts that have issued a 1 year AMED price target, the average AMED price target is $159.50, with the highest AMED stock price forecast at $221.00 and the lowest AMED stock price forecast at $95.00.

On average, Wall Street analysts predict that Amedisys's share price could reach $159.50 by Aug 2, 2023. The average Amedisys stock price prediction forecasts a potential upside of 50.32% from the current AMED share price of $106.11.

What is AMED's Earnings Per Share (EPS) forecast for 2022-2024?

(NASDAQ: AMED) Amedisys's current Earnings Per Share (EPS) is $4.31. On average, analysts forecast that AMED's EPS will be $5.34 for 2022, with the lowest EPS forecast at $5.19, and the highest EPS forecast at $5.44. On average, analysts forecast that AMED's EPS will be $5.95 for 2023, with the lowest EPS forecast at $5.55, and the highest EPS forecast at $6.43. In 2024, AMED's EPS is forecast to hit $6.91 (min: $5.78, max: $7.63).

What is AMED's forecast return on equity (ROE) for 2022-2025?

(NASDAQ: AMED) forecast ROE is 19.78%, which is considered weak.
©2022 WallStreetZen
Company
AboutBlogPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContact
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market Industries
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
Social
TwitterYouTube
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.